Reagan, John LFast, Loren DSafran, HowardNevola, MarthaWiner, Eric SCastillo, JorgeButera, James NQuesenberry, Matthew IYoung, Carolyn TQuesenberry, Peter J.2021-09-012013-06-19Reagan, John L, Loren D Fast, Howard Safran, Martha Nevola, Eric S Winer, Jorge Castillo, James N Butera et al. "Cellular Immunotherapy for Refractory Hematological Malignancies." Journal of Translational Medicine 11, no. 1 (2013): 150. DOI: 10.1186/1479-5876-11-1501479-5876https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37369248Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on achieving complete remission of disease in order to proceed with a consolidative stem cell transplant. At issue with this paradigm is the multitude of patients who are unable to achieve complete remission with standard chemotherapeutic options. A major benefit of transplantation is the graft versus tumor effect that follows successful engraftment. However, with this graft versus tumor effect comes the risk of graft versus host disease. Therefore, alternative treatment options that utilize immunotherapy while minimizing toxicity are warranted. Herein, we propose a novel treatment protocol in which haploidentical peripheral blood stem cells are infused into patients with refractory hematological malignancies. The end goal of cellular therapy is not engraftment but instead is the purposeful rejection of donor cells so as to elicit a potent immune reaction that appears to break host tumor tolerance.en-USResearch Subject Categories::MEDICINE::Microbiology, immunology, infectious diseases::Immunology::Tumour immunologyResearch Subject Categories::MEDICINE::Dermatology and venerology,clinical genetics, internal medicine::Internal medicine::HaematologyJournal Article2017-08-1520132021-09-0110.1186/1479-5876-11-150